These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 14524732)
41. Efficacy of omeprazole in lower grades of gastro-oesophageal reflux disease. Havelund T; Laursen LS; Lauritsen K Scand J Gastroenterol Suppl; 1994; 201():69-73. PubMed ID: 8047827 [TBL] [Abstract][Full Text] [Related]
42. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. DeVault KR Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():33-9. PubMed ID: 16483268 [TBL] [Abstract][Full Text] [Related]
43. Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease. Størdal K; Johannesdottir GB; Bentsen BS; Knudsen PK; Carlsen KC; Closs O; Handeland M; Holm HK; Sandvik L Arch Dis Child; 2005 Sep; 90(9):956-60. PubMed ID: 16113133 [TBL] [Abstract][Full Text] [Related]
44. The impact of gastroesophageal reflux disease on quality of life. Kamolz T; Pointner R; Velanovich V Surg Endosc; 2003 Aug; 17(8):1193-9. PubMed ID: 12799881 [TBL] [Abstract][Full Text] [Related]
45. Use of antisecretory agents as a trial of therapy. Fennerty MB Gut; 2002 May; 50 Suppl 4(Suppl 4):iv63-6. PubMed ID: 11953352 [TBL] [Abstract][Full Text] [Related]
46. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Langtry HD; Wilde MI Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507 [TBL] [Abstract][Full Text] [Related]
47. Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease. Scholten T; Teutsch I; Bohuschke M; Gatz G Clin Drug Investig; 2007; 27(4):287-96. PubMed ID: 17358101 [TBL] [Abstract][Full Text] [Related]
49. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G; Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305 [TBL] [Abstract][Full Text] [Related]
50. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Malfertheiner P; Lind T; Willich S; Vieth M; Jaspersen D; Labenz J; Meyer-Sabellek W; Junghard O; Stolte M Gut; 2005 Jun; 54(6):746-51. PubMed ID: 15888776 [TBL] [Abstract][Full Text] [Related]
51. Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity. Revicki DA; Zodet MW; Joshua-Gotlib S; Levine D; Crawley JA Health Qual Life Outcomes; 2003 Nov; 1():73. PubMed ID: 14641914 [TBL] [Abstract][Full Text] [Related]
53. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Caos A; Breiter J; Perdomo C; Barth J Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056 [TBL] [Abstract][Full Text] [Related]
54. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Revicki DA; Sorensen S; Maton PN; Orlando RC Dig Dis; 1998; 16(5):284-91. PubMed ID: 9892788 [TBL] [Abstract][Full Text] [Related]
55. Gastroesophageal reflux disease presenting as xerophthalmia. Davitt BV; Berdy G; Kane RE J Pediatr Ophthalmol Strabismus; 2001; 38(5):315-7. PubMed ID: 11587183 [No Abstract] [Full Text] [Related]
56. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Bell NJ; Burget D; Howden CW; Wilkinson J; Hunt RH Digestion; 1992; 51 Suppl 1():59-67. PubMed ID: 1397746 [TBL] [Abstract][Full Text] [Related]
57. Lansoprazole: in the management of gastroesophageal reflux disease in children. Scott LJ Paediatr Drugs; 2003; 5(1):57-61; discussion 62. PubMed ID: 12513106 [TBL] [Abstract][Full Text] [Related]
58. Health-related quality of life in patients with gastro-oesophageal reflux disease under routine care: 5-year follow-up results of the ProGERD study. Nocon M; Labenz J; Jaspersen D; Leodolter A; Richter K; Vieth M; Lind T; Malfertheiner P; Willich SN Aliment Pharmacol Ther; 2009 Mar; 29(6):662-8. PubMed ID: 19183146 [TBL] [Abstract][Full Text] [Related]
59. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Wiklund I; Bardhan KD; Müller-Lissner S; Bigard MA; Bianchi Porro G; Ponce J; Hosie J; Scott M; Weir D; Fulton C; Gillon K; Peacock R Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):19-27. PubMed ID: 9615259 [TBL] [Abstract][Full Text] [Related]
60. Heartburn in patients with gastro-oesophageal reflux disease in Germany and Sweden: a study on patients' burden of disease. Jones R; Horbach S; Sander P; Rydén-Bergsten T Pharmacoeconomics; 2003; 21(15):1091-102. PubMed ID: 14596628 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]